Canaccord Genuity Assumes AcelRx Pharmaceuticals (ACRX) at Buy, Catalyst-Heavy
Tweet Send to a FriendGet Alerts ACRX Hot Sheet
Price: $7.86 +5.50%
Rating Summary:
7 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Rating Summary:
7 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Trade ACRX Now!
Canaccord Genuity assumes coverage on AcelRx Pharmaceuticals (NASDAQ: ACRX) with a Buy. PT $8.00.
"We’re assuming coverage of AcelRx (ACRX) and setting a price target of $8 ahead of key data that could boost confidence in lead drug ARX-01 for post-operative analgesia using the company’s transmucosal sufentanil-based drug device therapy," analyst Randall Stanicky said. "Market potential is sizable and we like the risk/reward, for those with risk appetite, ahead of important year-end data. Focus on the Phase III data comparator data to IV PCA morphine, the current standard of care, as the key catalyst which we expect over the next month or so."
For an analyst ratings summary and ratings history on AcelRx Pharmaceuticals click here. For more ratings news on AcelRx Pharmaceuticals click here.
Shares of AcelRx Pharmaceuticals closed at $3.09 yesterday, with a 52 week range of $1.76-$4.00.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
"We’re assuming coverage of AcelRx (ACRX) and setting a price target of $8 ahead of key data that could boost confidence in lead drug ARX-01 for post-operative analgesia using the company’s transmucosal sufentanil-based drug device therapy," analyst Randall Stanicky said. "Market potential is sizable and we like the risk/reward, for those with risk appetite, ahead of important year-end data. Focus on the Phase III data comparator data to IV PCA morphine, the current standard of care, as the key catalyst which we expect over the next month or so."
For an analyst ratings summary and ratings history on AcelRx Pharmaceuticals click here. For more ratings news on AcelRx Pharmaceuticals click here.
Shares of AcelRx Pharmaceuticals closed at $3.09 yesterday, with a 52 week range of $1.76-$4.00.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Canaccord Boosts PT on AcelRx (ACRX) to $11; On Track for Sufentanil NDA Submission by Q313
- Topeka Capital Starts RDA Microelectronics (RDA) at Buy
- Topeka Capital Starts Atmel (ATML) at Buy
Create E-mail Alert Related Categories
New CoverageRelated Entities
Canaccord Genuity
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
